文献速递慢性肾脏病急性肾损伤

丙酸和丁酸对抗肾损伤及慢性肾脏病进展

Propionate and butyrate counteract renal damage and progression to chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

该研究测量了54例不同分期慢性肾脏病(CKD)患者的短链脂肪酸水平,发现粪便丙酸和丁酸随疾病进展逐渐降低,并与血清肌酐、血尿素氮和估算肾小球滤过率密切相关。体外实验显示丙酸和丁酸联合下调肿瘤坏死因子-α诱导的103个炎症和免疫相关基因;在小鼠叶酸诱导的急性肾损伤向CKD转化模型中,早期给予丙酸和丁酸可预防或减缓肾损伤进展。

要点

  • CKD患者粪便丙酸和丁酸水平随疾病进展逐渐降低,与肾功能指标相关。
  • 丙酸和丁酸联合下调肾小管细胞中肿瘤坏死因子-α诱导的103个炎症和免疫相关基因。
  • 小鼠模型中早期给予丙酸和丁酸可预防或减缓急性肾损伤向CKD的进展。

核心结论

  • CKD患者丙酸和丁酸水平与肾功能进行性丧失相关。
  • 在急性肾损伤临床前模型中早期给予丙酸和丁酸可预防疾病进展,显示独立于肠道菌群的治疗潜力。

研究设计与样本

  • 测量54例不同分期CKD患者的短链脂肪酸水平,分析其与肾功能和炎症参数的关系。
  • 利用全基因组表达分析研究丙酸和丁酸对炎症条件下肾小管细胞通路的影响。
  • 采用叶酸诱导的急性肾损伤向CKD转化的小鼠模型,分析丙酸和丁酸的预防和治疗潜力。

主要发现

  • CKD患者粪便丙酸和丁酸水平随疾病进展逐渐降低,与血清肌酐、血尿素氮和估算肾小球滤过率密切关联。
  • 丙酸和丁酸联合下调肿瘤坏死因子-α诱导的103个与炎症过程和免疫系统激活相关的基因表达。
  • 在小鼠模型中,损伤前或损伤后不久分别给予丙酸和丁酸,可预防和减缓损伤进展,表现为肾损伤标志物、促炎和促纤维化标志物表达降低,以及长期肾功能恢复。

临床怎么用

  • 丙酸和丁酸水平可能作为CKD进展的监测指标。
  • 早期补充丙酸和丁酸可能成为延缓急性肾损伤向CKD进展的治疗策略,但需临床验证。

局限性

  • 研究为观察性临床关联分析加临床前动物模型,尚未在人体中验证治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, are produced by gut microbiota through fermentation of complex carbohydrates that cannot be digested by the human host. They affect gut health and can contribute at the distal level to the pathophysiology of several diseases, including renal pathologies. METHODS: SCFA levels were measured in chronic kidney disease (CKD) patients (n = 54) at different stages of the disease, and associations with renal function and inflammation parameters were examined. The impact of propionate and butyrate in pathways triggered in tubular cells under inflammatory conditions was analysed using genome-wide expression assays. Finally, a pre-clinical mouse model of folic acid-induced transition from acute kidney injury to CKD was used to analyse the preventive and therapeutic potential of these microbial metabolites in the development of CKD. RESULTS: Faecal levels of propionate and butyrate in CKD patients gradually reduce as the disease progresses, and do so in close association with established clinical parameters for serum creatinine, blood urea nitrogen and the estimated glomerular filtration rate. Propionate and butyrate jointly downregulated the expression of 103 genes related to inflammatory processes and immune system activation triggered by tumour necrosis factor-α in tubular cells. In vivo, the administration of propionate and butyrate, either before or soon after injury, respectively, prevented and slowed the progression of damage. This was indicated by a decrease in renal injury markers, the expression of pro-inflammatory and pro-fibrotic markers, and recovery of renal function over the long term. CONCLUSIONS: Propionate and butyrate levels are associated with a progressive loss of renal function in CKD patients. Early administration of these SCFAs prevents disease advancement in a pre-clinical model of acute renal damage, demonstrating their therapeutic potential independently of the gut microbiota.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Corte-Iglesias V, Saiz ML, Andrade-Lopez AC, et al. Propionate and butyrate counteract renal damage and progression to chronic kidney disease. Nephrol Dial Transplant. 2024. PMID: 38794880. doi:10.1093/ndt/gfae118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。